United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - maraviroc (unii: md6p741w8a) (maraviroc - unii:md6p741w8a) - maraviroc tablets are indicated in combination with other antiretroviral agents for the treatment of only ccr5-tropic human immunodeficiency virus type 1 (hiv-1) infection in adult and pediatric patients 2 years of age and older weighing at least 10 kg. limitations of use: • maraviroc tablets are not recommended in patients with dual/mixed- or cxcr4-tropic hiv-1 [ see microbiology ( 12.4) ]. maraviroc tablets are contraindicated in patients with severe renal impairment or esrd (crcl less than 30 ml per minute) who are concomitantly taking potent cyp3a inhibitors or inducers [ see warnings and precautions ( 5.3) ]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to maraviroc during pregnancy. physicians are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary limited data on the use of maraviroc during pregnancy from the apr and case reports are not suffi

United States - English - NLM (National Library of Medicine)

xlcare pharmaceuticals inc. - maraviroc (unii: md6p741w8a) (maraviroc - unii:md6p741w8a) - maraviroc tablets are indicated in combination with other antiretroviral agents for the treatment of only ccr5-tropic human immunodeficiency virus type 1 (hiv-1) infection in adult and pediatric patients 2 years of age and older weighing at least 10 kg. limitations of use: • maraviroc tablets are not recommended in patients with dual/mixed- or cxcr4-tropic hiv-1 [see microbiology ( 12.4)]. maraviroc tablets are contraindicated in patients with severe renal impairment or esrd (crcl less than 30 ml per minute) who are concomitantly taking potent cyp3a inhibitors or inducers [see warnings and precautions ( 5.3)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to maraviroc during pregnancy. physicians are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary limited data on the use of maraviroc during pregnancy from the apr and

United States - English - NLM (National Library of Medicine)

viiv healthcare company - maraviroc (unii: md6p741w8a) (maraviroc - unii:md6p741w8a) - maraviroc 25 mg - selzentry is indicated in combination with other antiretroviral agents for the treatment of only ccr5‑tropic human immunodeficiency virus type 1 (hiv‑1) infection in adult and pediatric patients weighing at least 2 kg. limitations of use selzentry is contraindicated in patients with severe renal impairment or esrd (creatinine clearance [crcl] less than 30 ml per minute) who are concomitantly taking potent cyp3a inhibitors or inducers [see warnings and precautions (5.3)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to selzentry during pregnancy. physicians are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary limited data on the use of selzentry during pregnancy from the apr and case reports are not sufficient to inform a drug-associated risk of birth defects and miscarriage. in animal reproduction studies, no evidence of adverse developmental outcomes was observed with

United States - English - NLM (National Library of Medicine)

i3 pharmaceuticals, llc - maraviroc (unii: md6p741w8a) (maraviroc - unii:md6p741w8a) - maraviroc is indicated in combination with other antiretroviral agents for the treatment of only ccr5‑tropic human immunodeficiency virus type 1 (hiv‑1) infection in adult and pediatric patients 2 years of age and older weighing at least 10 kg. limitations of use - maraviroc is not recommended in patients with dual/mixed- or cxcr4-tropic hiv- 1 [see microbiology (12.4)] . maraviroc is contraindicated in patients with severe renal impairment or esrd (creatinine clearance [crcl] less than 30 ml per minute) who are concomitantly taking potent cyp3a inhibitors or inducers [see warnings and precautions (5.3)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to maraviroc during pregnancy. physicians are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary limited data on the use of maraviroc during pregnancy from the apr and case reports are not sufficient to

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - maraviroc, quantity: 300 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; sodium starch glycollate; calcium hydrogen phosphate; colour - celsentri, in combination with other antiretroviral medicinal products, is indicated for adult patients infected with only ccr5-tropic hiv-1.,the use of other active agents with celsentri is associated with a greater likelihood of treatment response.

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - maraviroc, quantity: 150 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; calcium hydrogen phosphate; microcrystalline cellulose; magnesium stearate; colour - celsentri, in combination with other antiretroviral medicinal products, is indicated for adult patients infected with only ccr5-tropic hiv-1. the use of other active agents with celsentri is associated with a greater likelihood of treatment response.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - maraviroc (unii: md6p741w8a) (maraviroc - unii:md6p741w8a) - maraviroc 300 mg - selzentry is indicated in combination with other antiretroviral agents for the treatment of only ccr5-tropic human immunodeficiency virus type 1 (hiv-1) infection in patients 2 years of age and older weighing at least 10 kg. limitations of use: selzentry is contraindicated in patients with severe renal impairment or esrd (crcl less than 30 ml per minute) who are concomitantly taking potent cyp3a inhibitors or inducers [see warnings and precautions (5.3)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to selzentry during pregnancy. physicians are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary limited data on the use of selzentry during pregnancy from the apr and case reports are not sufficient to inform a drug-associated risk of birth defects and miscarriage. in animal reproduction studies, no evidence of adverse developmental outcomes was observed with maraviroc. durin

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - maraviroc -

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - maraviroc -

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - maraviroc - film coated tablets - maraviroc 150 mg - maraviroc - maraviroc - celsentri is a ccr5 co-receptor antagonist indicated for combination antiretroviral treatment of adults infected with only ccr5-tropic hiv-1.• in treatment-naïve subjects, more subjects treated with celsentri experienced virologic failure and developed lamivudine resistance compared to efavirenz.• tropism testing with a highly sensitive tropism assay is required for the appropriate use of celsentri.